Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 3275096, 12 pages
https://doi.org/10.1155/2017/3275096
Research Article

iTRAQ-Based Quantitative Proteomics Analysis of the Protective Effect of Yinchenwuling Powder on Hyperlipidemic Rats

Institute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha 410008, China

Correspondence should be addressed to Dongsheng Wang; moc.621@666hsdw

Received 24 January 2017; Revised 16 May 2017; Accepted 8 June 2017; Published 14 August 2017

Academic Editor: Jae Youl Cho

Copyright © 2017 Zheyu Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Navar-Boggan, E. D. Peterson, R. B. D'Agostino, B. Neely, A. D. Sniderman, and M. J. Pencina, “Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease,” Circulation, vol. 131, no. 5, pp. 451–458, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. R. Meyers and N. Gokce, “Endothelial dysfunction in obesity: Etiological role in atherosclerosis,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 14, no. 5, pp. 365–369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Magné, J. F. Huneau, D. Tsikas et al., “Rapeseed protein in a high-fat mixed meal alleviates postprandial systemic and vascular oxidative stress and prevents vascular endothelial dysfunction in healthy rats,” Journal of Nutrition, vol. 139, no. 9, pp. 1660–1666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T.-L. Yang, M.-F. Chen, X. Xia, B.-L. Luo, and Y.-J. Li, “Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia,” European Journal of Clinical Pharmacology, vol. 62, no. 3, pp. 179–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. S. Wang, H. Zhou, and X. W. Yin, “Lipid modulating with clearing heat and promoting diuresis method:a clinical observation,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 8, no. 5, pp. 50-51, 2001. View at Google Scholar
  6. D. S. Wang, H. Zhou, J. S. Li, and C. K. Xi, “Treating hyperlipidemia with Yinchenwuling Powder:a clinical observation,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 16, no. 5, pp. 36–39, 2001. View at Google Scholar
  7. M. Yang, D. S. Wang, and X. J. Mao, “Effects of Yinchenwuling Powder onhemorheology and cell apoptosis in atherosclerosis rats,” Journal of New Chinese Medicine, vol. 38, no. 11, pp. 84–86, 2006. View at Google Scholar
  8. R. M. Li, L. L. Zhao, and D. S. Wang, “Meta analysis of Yinchenwulin Powder on Hyperlipidemia,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 21, no. 5, pp. 197–201, 2015. View at Google Scholar
  9. R. Yu, Y. J. Wu, and H. Zhou, “Experimental studies on effect of Yinchen WulingPowder on hyperlipoproteinemia and its lipid peroxidation,” Journal of Traditional Chinese Medicine, vol. 38, no. 2, pp. 104–107, 1997. View at Google Scholar
  10. A. S. Wei, J. H. Ye, K. P. Jiang et al., “Effects of Yinchenwuling Powder on serum inflammatory biomarkers in metabolic syndromepatients,” Shandong Journal of Traditional Chinese Medicine, vol. 26, no. 1, pp. 16–18, 2007. View at Google Scholar
  11. R. Li, L. Zhao, N. Wu et al., “Proteomic analysis allows for identifying targets of Yinchenwuling Powder in hyperlipidemic rats,” Journal of Ethnopharmacology, vol. 185, pp. 60–67, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. J. R. Wiśniewski, A. Zougman, N. Nagaraj, and M. Mann, “Universal sample preparation method for proteome analysis,” Nature Methods, vol. 6, no. 5, pp. 359–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Kambiranda, R. Katam, S. M. Basha, and S. Siebert, “iTRAQ-based quantitative proteomics of developing and ripening muscadine grape berry,” Journal of Proteome Research, vol. 13, no. 2, pp. 555–569, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Lan, W. Li, and W. Schmidt, “Complementary proteome and transcriptome profiling in phosphate-deficient arabidopsis roots reveals multiple levels of gene regulation,” Molecular and Cellular Proteomics, vol. 11, no. 11, pp. 1156–1166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Verdeguer, C. Castro, M. Kubicek et al., “Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation,” Cardiovascular Research, vol. 76, no. 2, pp. 340–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. W. S. Speidl, M. Exner, J. Amighi et al., “Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis,” European Heart Journal, vol. 26, no. 21, pp. 2294–2299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. K. M. Kostner, R. B. Fahti, C. Case, P. Hobson, J. Tate, and T. H. Marwick, “Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease,” Clinica Chimica Acta, vol. 365, no. 1-2, pp. 129–134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. M. Liu, X. Yan, and Y. Y. Liu, “Complement and atherosclerosis,” Chinese Journal of Cardiology, vol. 33, no. 9, pp. 866–869, 2005. View at Google Scholar
  19. Y. Nakaya, E. J. Schaefer, and H. B. Brewer Jr., “Activation of human post heparin lipoprotein lipase by apolipoprotein H (β-glycoprotein I),” Biochemical and Biophysical Research Communications, vol. 95, no. 3, pp. 1168–1172, 1980. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Wurm, E. Beubler, E. Polz, A. Holasek, and G. Kostner, “Studies on the possible function of β2-glycoprotein-I: influence in the triglyceride metabolism in the rat,” Metabolism, vol. 31, no. 5, pp. 484–486, 1982. View at Publisher · View at Google Scholar · View at Scopus
  21. T. McNally, M. Crook, I. J. Mackie, D. A. Isenberg, and S. J. Machin, “β2 glycoprotein-I antigen is increased in primary hyperlipidaemia,” British Journal of Haematology, vol. 88, no. 2, pp. 424–426, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Crook, “Apolipoprotein H: Its relevance to cardiovascular disease,” Atherosclerosis, vol. 209, no. 1, pp. 32–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. George, A. Afek, B. Gilburd et al., “Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I,” Circulation, vol. 98, no. 11, pp. 1108–1115, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Nigro, O. Scudiero, M. L. Monaco et al., “New insight into adiponectin role in obesity and obesity-related diseases,” BioMed Research International, vol. 2014, Article ID 658913, 14 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. P. A. Kern, G. B. di Gregorio, T. Lu, N. Rassouli, and G. Ranganathan, “Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression,” Diabetes, vol. 52, no. 7, pp. 1779–1785, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Lee and J. Shao, “Adiponectin and energy homeostasis,” Reviews in Endocrine and Metabolic Disorders, vol. 15, no. 2, pp. 149–156, 2014. View at Publisher · View at Google Scholar
  27. K. Ohashi, N. Ouchi, and Y. Matsuzawa, “Anti-inflammatory and anti-atherogenic properties of adiponectin,” Biochimie, vol. 94, no. 10, pp. 2137–2142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. B. Schulze, E. B. Rimm, I. Shai, N. Rifai, and F. B. Hu, “Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes,” Diabetes Care, vol. 27, no. 7, pp. 1680–1687, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Do, J. Alvarez, E. Chiquette, and R. Chilton, “The good fat hormone: adiponectin and cardiovascular disease,” Current Atherosclerosis Reports, vol. 8, no. 2, pp. 94–99, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. W. Steffes, M. D. Gross, D.-H. Lee, P. J. Schreiner, and D. R. Jacobs Jr., “Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the coronary artery risk development in young adults study,” Obesity, vol. 14, no. 2, pp. 319–326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Li, W.-Q. Wang, H. Zhang et al., “Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity,” American Journal of Physiology: Endocrinology and Metabolism, vol. 293, no. 6, pp. E1703–E1708, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. G. A. Rabinovich, M. A. Toscano, J. M. Ilarregui, and N. Rubinstein, “Shedding light on the immunomodulatory properties of galectins: Novel regulators of innate and adaptive immune responses,” Glycoconjugate Journal, vol. 19, no. 7-9, pp. 565–573, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. N. L. Perillo, K. E. Pace, J. J. Seilhamer, and L. G. Baum, “Apoptosis of T cells mediated by galectin-1,” Nature, vol. 378, no. 6558, pp. 736–739, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. C. D. Chung, V. P. Patel, M. Moran, L. A. Lewis, and M. C. Miceli, “Galectin-1 induces partial TCR ζ-chain phosphorylation and antagonizes processive TCR signal transduction,” Journal of Immunology, vol. 165, no. 7, pp. 3722–3729, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Escoda-Ferran, E. Carrasco, M. Caballero-Baños et al., “Modulation of CD6 function through interaction with Galectin-1 and -3,” FEBS Letters, vol. 588, no. 17, pp. 2805–2813, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. D. H. Rhodes, M. Pini, K. J. Castellanos et al., “Adipose tissue-specific modulation of galectin expression in lean and obese mice: Evidence for regulatory function,” Obesity, vol. 21, no. 2, pp. 310–319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. E. P. Moiseeva, Q. Javed, E. L. Spring, and D. P. De Bono, “Galectin 1 is involved in vascular smooth muscle cell proliferation,” Cardiovascular Research, vol. 45, no. 2, pp. 493–502, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. P. J. Lefbvrè and A. J. Scheen, “The postprandial state and riskof cardiovascular disease,” Diabet Medicine, vol. 15, supplement 4, pp. S63–S68, 1998. View at Publisher · View at Google Scholar
  39. L. M. Canseco-Avila, C. Jerjes-Sánchez, R. Ortiz-L et al., ““Fibrinogen. Cardiovascular risk factor or marker?” Archivos de Cardiología de México, vol. 76, supplement 4, pp. S158–S172, 2006. View at Google Scholar
  40. E. B. Smith, “Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis,” Clinics in Haematology, vol. 15, no. 2, pp. 355–370, 1986. View at Google Scholar · View at Scopus
  41. E. Ernst, “Fibrinogen: An important risk factor for atherothrombotic diseases,” Annals of Medicine, vol. 26, no. 1, pp. 15–22, 1994. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Langhauser, E. Göb, P. Kraft et al., “Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation,” Blood, vol. 120, no. 19, pp. 4082–4092, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Wu, “Contact pathway of coagulation and inflammation,” Thrombosis Journal, vol. 13, no. 17, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Puccetti, F. Bruni, and M. Renzo, “Hypercoagulable state inhypercholesterolemic subjects assessed by platelet dependent thrombin generation: in vitro effect of cerivastatin, European review formedical and pharmacological sciences,” ’European Review Formedical And Pharmacological Sciences, vol. 3, no. 5, pp. 197–204, 1999. View at Google Scholar
  45. K. Ranganna, O. P. Mathew, F. M. Yatsu, Z. Yousefipour, B. E. Hayes, and S. G. Milton, “Involvement of glutathione/glutathione S-transferase antioxidant system in butyrate-inhibited vascular smooth muscle cell proliferation,” FEBS Journal, vol. 274, no. 22, pp. 5962–5978, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Del Boccio, D. Lapenna, E. Porreca et al., “Aortic antioxidant defence mechanisms: time-related changes in cholesterol-fed rabbits,” Atherosclerosis, vol. 81, no. 2, pp. 127–135, 1990. View at Publisher · View at Google Scholar · View at Scopus